Tag: results

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Joins Workhorse’s proven vehicles, manufacturing capabilities and national dealer network with Motiv’s diverse product portfolio and top fleet relationships

Shrisha Radhakrishna appointed as President and interim leader of Opendoor

Continued progress across pipeline programs with focus on pancreatic cancer

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

BOCA RATON, FL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it now holds approximately 1,420,173 SOL and SOL equivalents on its balance sheet, inclusive of rewards generated through staking and onchain activities. The increase follows the Company’s acquisition of 110,000 SOL at an average price of $201.68, representing a total value of approximately $22 million.

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.